Justin Smith, MD
Family Practice · Rome, GANPI 1982015590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.1% of the total. 2025 is the largest year on record at $691, 3.6 times the $192 reported in 2019. Among family practice clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$795
- Amgen$344
- AstraZeneca$301
- GSK$253
- Lilly USA, LLC$224
- Novo Nordisk$112
- plus $524 from 13 others
What the payments were for
- Food & beverage$2,52399%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $795 |
| Amgen | 21 | $344 |
| AstraZeneca | 19 | $301 |
| GSK | 17 | $253 |
| Lilly USA, LLC | 14 | $224 |
| Novo Nordisk | 8 | $112 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $87 |
| Pfizer | 4 | $78 |
| Abbott | 3 | $65 |
| Shield Therapeutics Inc | 4 | $63 |
| Cardiva Medical, Inc. | 1 | $52 |
| Exact Sciences | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Mylan Specialty L.p. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
How this compares
$2,553 in reported general payments places this provider in the 95th percentile of 193 family practice providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $174,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $74,167 |
| MounjaroTirzepatide | 47 | $67,252 |
| FarxigaDapagliflozin Propanediol | 82 | $58,672 |
| JardianceEmpagliflozin | 72 | $57,300 |
| EliquisApixaban | 72 | $56,114 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $35,310 |
| VraylarCariprazine Hcl | 12 | $26,238 |
| LinzessLinaclotide | 38 | $22,712 |
| EntrestoSacubitril/Valsartan | 30 | $20,677 |
| MyrbetriqMirabegron | 28 | $18,024 |
| XareltoRivaroxaban | 19 | $17,621 |
| WegovySemaglutide | 12 | $16,103 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $15,574 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $112 | $190,513162 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $253 | $80,879127 claims |
| Lilly USA, LLCMounjaro | $224 | $67,25247 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $301 | $65,05797 claims |
| PfizerEliquis | $78 | $56,11472 claims |
| AbbVieVraylar, Linzess, Synthroid | $795 | $51,20382 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $5,87412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 family practice providers in Georgia.
Other family practice in Rome
- Christopher WoodRome$0
- Laurie UrquhartRome$0
- Claire-Louise YoungDalton$115
- Lachmi BaiColumbus$85
- Manasa ValluriColumbus$69
- Monique Merritt AtkinsStone Mountain$61
- Jamin GrahamMarietta$29
- Jessica OrduLithonia$22
- Michelle KalejaiyeMarietta$16
- Nosheen AzamWaycross$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.